Revenue: Increased 12.6% year-over-year to $207.4 million. Net Income: Increased 47% to $11.4 million. Diluted Earnings Per Share: $0.21. Adjusted EBITDA: Grew 27.8% year-over-year to $28.9 million. Average Full-Time Active Students: Increased 10.3% year-over-year to 24,604 students. New Student Starts: Grew 21.4% year-over-year to 6,650 starts. Concorde Division Revenue: $73.2 million, an increase of 20.3% over the prior year quarter. UTI Division Revenue: $134.2 million, an increase of 8.8% over the prior year quarter. Total Available Liquidity: $235 million, including $40 million of short-term investments and $99 million of remaining capacity on the revolving credit facility. Operating Cash Flow Year-to-Date: $22.2 million. Adjusted Free Cash Flow Year-to-Date: $8 million. Capital Expenditures Year-to-Date: $14.3 million. Fiscal 2025 Revenue Guidance: Raised to $825 million to $835 million, reflecting approximately 13% year-over-year growth. Fiscal 2025 Adjusted EBITDA Guidance: Raised to $124 million to $128 million. Fiscal 2025 New Student Starts Guidance: Expected to be between 29,000 and 30,000. Warning! GuruFocus has detected 7 Warning Sign with UTI. Release Date: May 07, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Revenue for the second quarter increased nearly 13% year-over-year to $207.4 million. Average full-time active students grew over 10% year-over-year to 24,604 students. Net income increased 47% to $11.4 million with diluted earnings per share of $0.21. Adjusted EBITDA grew approximately 28% year-over-year to $28.9 million. Strong demand for skilled labor, particularly in trades and healthcare, continues to provide tailwinds for UTI's business. Negative Points Potential challenges in maintaining high double-digit growth in Concorde division due to capacity limits in clinical courses. Increased strategic investments in fiscal years 2026 and 2027 may temporarily moderate margin growth. The number of for-sale signs in the market for strategic acquisitions is smaller than expected. High school student recruitment is largely complete for the year, which may impact future enrollment growth rates. The company is facing tougher comparable periods for new student starts in the upcoming quarters. Q & A Highlights Q: Can you highlight any specific campuses or programs that contributed to the strong new student starts? Also, what are the favorable tailwinds you mentioned in the press release? A: Jerome Grant, CEO: The strong new student starts are driven by increased marketing investments, particularly in the healthcare side, with clinical courses showing significant strength. The favorable tailwinds include a growing preference for trade schools over 4-year colleges, increased demand for skilled labor, and supportive political environments focusing on onshoring and infrastructure development. Story Continues Q: How does the enrollment growth break out for UTI and Concorde in the third and fourth quarters? Was the increase in new start guidance driven by one segment? A: Jerome Grant, CEO: Concorde's growth is approaching capacity in clinical courses, making it challenging to maintain high double-digit growth. UTI's growth is driven by skilled trades, with high school students filling seats in auto diesel programs. The growth trajectory is expected to be high single digits in Q3 and mid-single digits in Q4. Q: Can you provide more details on the EBITDA growth trajectory for 2026 and 2027? A: Jerome Grant, CEO: We anticipate higher strategic investments in 2026 and 2027, which will limit EBITDA growth rates until new campuses and programs scale in 2028 and 2029. Bruce Schuman, CFO, added that revenue growth is expected to be linear, with accelerated EBITDA growth anticipated by 2029. Q: What are the trends in employer demand for transportation, skilled trades, and healthcare graduates? A: Jerome Grant, CEO: Demand in transportation remains steady with multiple job opportunities per graduate. Skilled trades are experiencing robust demand, particularly for welders, electricians, and HVAC technicians. Healthcare demand is strong, with Concorde's marketing and admissions efforts capturing more of this demand. Q: What is the current level of activity in corporate development efforts, and how have seller attitudes changed? A: Jerome Grant, CEO: There is slightly less activity in the market as demand for skilled trades and healthcare increases. The number of opportunities for sale is smaller than expected, but we continue to explore strategic acquisitions. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
Universal Technical Institute Inc (UTI) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ...
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...